TEH Bin Tean

Our team at CSI is part of the multi-institutional Cancer Epigenome research laboratory (http://tbtlab.org/), which focuses on integrated epigenomic and genomic profiling in Asian cancers using enabling technologies such as ChIP-Seq, RNA-seq, Whole-genome and DNA methylation sequencing. The data is then correlated with clinicopathological information including how patients respond to certain drugs. The group always emphasizes on collaboration (both local and international) which is key to scientific breakthroughs.

Biosketch

Senior Principal Investigator, Cancer Science Institute of Singapore, NUS
Deputy Director (Research), National Cancer Centre Singapore
Deputy Director (Scientific), SingHealth Duke-NUS Institute of Precision Medicine
Professor, Duke-NUS Medical School, Singapore
Senior Principal Investigator, Institute of Molecular and Cell Biology, Singapore

Year(s) Degree (if applicable) Institute
1997 Ph.D. Karolinska Institute, Sweden
1992 M.D. University of Queensland, Australia

Senior Principal Investigator, Cancer Science Institute of Singapore
Deputy Director (Research), National Cancer Centre Singapore
Deputy Director (Scientific), SingHealth Duke-NUS Institute of Precision Medicine (PRISM)
Principal Investigator, Laboratory of Cancer Epigenome, National Cancer Centre Singapore
Professor, Duke-NUS Medical School, Singapore
Senior Principal Investigator, Institute of Molecular and Cell Biology, Singapore

2015 President’s Science Award
2015 SingHealth Excellence Awards – Distinguised Researcher Award
2015 – 2020 Singapore Translational Research Investigator Award
2014 American Society for Clinical Investigation (ASCI)
2013 Honorable Member, Romanian Academy of Medical Sciences
2008 University of Queensland International Alumnus of the Year Highly Commended Nominee, Australia
2008 Malaysian Distinguished Visiting Scientist Award by Ministry of Science and Technology

Research

We have characterised the genomic landscapes of several tumour types that are more prevalent in the Asian population, such as upper urinary tract urothelial cancer in Taiwan, cholangiocarcinoma in the north-east of Thailand, NK/T-cell lymphoma, and fibroepithelial tumours of the breast. As part of the Cancer Epigenome research laboratory , our team at CSI is focused on protein structural biology and drug discovery. Our research goals are:

i. To identify the genetic features of various types of tumors, including mutational profiles and gene signatures, by next generation sequencing approaches.
ii. To investigate the functional implications and mechanisms of such genetic alterations by biochemical assays and structural studies.
iii. To discover potential therapeutics based on our mechanistic understanding of the tumor-associated mutant proteins.

We emphasize on team science and collaborate widely with experts from within and outside of the country. We work closely with clinicians, including oncologists, surgeons and pathologists, to understand the clinical implications of our findings, particularly how the mutations in these genes are correlated with various clinical-pathological parameters (tumour grade, stage, survival, and drug response). We also collaborate with pharmaceutical and biotechnology companies to further investigate drug targets and mechanisms. As a dynamic team, we strive towards a common goal of developing personalized medicine for cancers through our combined and continuous effort in making new discoveries and translating them into novel diagnostics and therapeutics.

Lab Members

Selected Publications

1. Ler LD, Ghosh S, Chai X, Thike AA, Heng HL, Siew EY, Dey S, Koh LK, Lim JQ, Lim WK, Myint SS, Loh JL, Ong P, Sam XX, Huang D, Lim T, Tan PH, Nagarajan S, Cheng CW, Ho H, Ng LG, Yuen J, Lin PH, Chuang CK, Chang YH, Weng WH, Rozen SG, Tan P, Creasy CL, Pang ST*, McCabe MT*, Poon SL*, Teh BT*. 2017. Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. Sci Transl Med. 2017 Feb 22;9(378). (*Co-corresponding author)

2. Fukawa T, Yan-Jiang BC, Min-Wen JC, Jun-Hao ET, Huang D, Qian CN, Ong P, Li Z, Chen S, Mak SY, Lim WJ, Kanayama HO, Mohan RE, Wang RR, Lai JH, Chua C, Ong HS, Tan KK, Ho YS, Tan IB, Teh BT, Shyh-Chang N. 2016. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia. Nature Medicine 22(6): 666–671, 2016

3. Tan J, Ong CK, Lim WK, Ng CC, Thike AA, Ng LM, Rajasegaran V, Myint SS, Nagarajan S, Thangaraju S, Dey S, Nasir ND, Wijaya GC, Lim JQ, Huang D, Li Z, Wong BH, Chan JY, McPherson JR, Cutcutache I, Poore G, Tay ST, Tan WJ, Putti TC, Ahmad BS, Iau P, Chan CW, Tang AP, Yong WS, Madhukumar P, Ho GH, Tan VK, Wong CY, Hartman M, Ong KW, Tan BK, Rozen SG, Tan P, Tan PH, Teh BT. 2015. Genomic landscapes of breast fibroepithelial tumors. Nature Genetics 47(11): 1341–1345, 2015

4. Poon SL, Huang MN, Choo Y, McPherson JR, Yu W, Heng HL, Gan A, Myint SS, Siew EY, Ler LD, Ng LG, Weng WH, Chuang CK, Yuen JS, Pang ST, Tan P, Teh BT, Rozen SG. 2015. Mutation signatures implicate aristolochic acid in bladder cancer development. Genome Medicine 7(1):38, 2015

5. Lim WK, Ong CK, Tan J, Thike AA, Ng CC, Rajasegaran V, Myint SS, Nagarajan S, Nasir ND, McPherson JR, Cutcutache I, Poore G, Tay ST, Ooi WS, Tan VK, Hartman M, Ong KW, Tan BK, Rozen SG, Tan PH, Tan P, Teh BT. 2014. Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nature Genetics 46(8): 877–880, 2014

6. Chan-on W, Nairismägi M-L, Ong CK, Dima S, Pairojkul C, Lim KH, McPherson JR, Lim WK, Cucutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Huat ITB, Duda D, Nastase A, Myint SS, Wong BH, Gan A, Rajasegaran V, Ng CCY, Jusakul A, Zhang S, Vohra P, Yu W, Huang D, Yongvanit P, Wongkham S, Khuntikeo N, Bhudhisawasdi V, Popescu I, Rozen SG, Tan P, Teh BT. 2013. Distinct mutational patters of infection and non-infection-related bile duct cancers revealed by exome sequencing. Nature Genetics 45(12): 1474–1478

7. Koo GC, Tan SY, Tang T, Poon SL, Allen GE, Tan L, Chong SC, Ong WS, Tay K, Tao M, Quek R, Loong S, Yeoh KW, Yap SP, Lee KA, Lim LC, Tan D, Goh C, Cutcutache I, Yu W, Ng CCY , Rajasegaran V, Heng HL, Gan A,  Ong CK, Rozen S, Tan P, Teh BT, Lim ST. 2012. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. Cancer Discov 2(7): 591–597

8. Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, McPherson J, Allen GE, Ng CCY, Wong BHM, Myint SS, Rajasegaran V, Heng HL, Gan A, Zang ZJ, Wu Y, Wu J, Lee MH, Huang D, Ong P, Chan-on W, Cao Y, Qian CN, Lim KH, Ooi A, Dykema KJ, Furge K, Kukongviriyapan V, Sripa B, Wongkham C, Yongvanit P, Futreal PA, Bhudhisawasdi V, Rozen S, Tan P, Teh BT. 2012. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nature Genetics 44(6): 690–693

9. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson J, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, Lim KH, Ong CK, Huang D, Chin SY, Tan IB, Ng CCY, Yu W, Wu Y, Lee M, Wu J, Poh D, Wan WK, Rha SY, So J, Salto-Tellez M, Yeoh KG, Wong WK, Futreal PA, Pang B, Ruan Y, Hillmer A, Bertrand D, Nagarajan N, Rozen S, Teh BT*, Tan P. Exome sequencing of gastric adenocarcinoma reveals recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nature Genetics 44(5): 570–574, 2012

10. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin M-L, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D, Greenman C, Hardy C, Jia M, Latimer C, Lau KW, Marshall J, McLaren S, Menzies A, Mudie L, Stebbings L, Largaespada DA, Wessels LFA, Richard S, Kahnoski RJ, Anema J, Tuveson D, Perez-Mancera P, Mustonen V, Fischer A, Adams DJ, Rust A, Chan-on W, Subimerb C, Dykema K, Furge K, Campbell PJ, Teh BT, Stratton MR, Futreal PA. 2011. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011: 469(7331): 539–542.  PMCID: PMC3030920 (Co-corresponding author)